New publication University of Wageningen in cooperation with the eNose Company
Home / All blogs
Breath analysis with Aeonose on Barrett’s Esophagus published by Mayo Clinic Rochester Minnesota
New paper available on Breath Analysis with Aeonose on Barrett’s Esophagus by Daniel K Chan et al, Mayo Clinic Rochester Minnesota.
Certificate for highly cited research
The editors of Tuberculosis are delighted to inform you that your paper, Diagnosis of active tuberculosis by e-nose analysis of exhaled air, published in 2013, is one of the most highly cited papers during 2014 and 2015. We would like to take this opportunity to thank you for publishing with us, and congratulate you.
Aeonose pilot study COPD exacerbations
Aeonose concept study Head and Neck
The eNose Company is per 30 maart 2016 ISO 13485 gecertificeerd!
Zorginnovatieprijs 2016 nominatie
The eNose Company is met de Aeonose® genomineerd voor de Zorginnovatieprijs 2016!
De prijs wordt uitgereikt op het Health Valley Event op 17 maart 2016. Het Health Valley Event is het grootste jaarlijkse congres op het gebied van zorginnovatie en trekt meer dan 1000 deelnemers. Tijdens het plenaire slotprogramma krijgen de drie genomineerde zorginnovaties de kans zich aan het grote publiek te presenteren. Het publiek in de zaal kiest uiteindelijk het winnende bedrijf.
Abstract presented at EBCC
Breast cancer diagnosis and subtyping by analysing exhaled breath: A pilot study using a portable electronic nose (Aeonose®) Timmer-Bonte1, S. Grosfeld1, N. Seelen-Janssen1, L. Veenendaal2, F. Zijlstra3.
1Alexander Monro Breast Cancer Hospital, Medical Oncology, Bilthoven, Netherlands; 2Alexander Monro Breast Cancer Hospital, Surgery, Bilthoven, Netherlands; 3Alexander Monro Breast Cancer Hospital, Radiology, Bilthoven, Netherlands
Background: Analysing exhaled breath is a rapidly emerging field of medical diagnostics. Growing evidence suggests pathological conditions can cause metabolic changes in the body resulting in deviations in volatile organic compounds (VOC’s) in exhaled breath. The hand-held electronic nose used in this pilot study is convenient to use and has already proven to be capable of distinguishing patients (pts) suffering from lung cancer and head and neck cancer from healthy controls. Advantages include non-invasiveness and fast results. The objective of the current study is to investigate if exhaled-breath patterns from breast cancer (BC) pts can be distinguished from pts with benign breast pathology or healthy controls.
Methods: Female pts referred to our breast cancer hospital for screening or on suspicion of BC, were subjected to standard diagnostic procedures as per protocol (with a minimum of clinical examination, mammography and in case of BIRADS >2 biopsy). All pts were asked written informed consent for performing an additional breath test. Pts had to breathe into the Aeonose® device (made available for this pilot study by The eNose Company, Zutphen, The Netherlands) for a period of 5 minutes. Collected measurement data were compressed using a Tucker3 algorithm followed by neural network analysis. In this way, the electronic nose has been trained to distinguish between healthy and affected pts.
Results: 185 pts were eligible; the majority was referred because of a palpable lesion or abnormal findings on mammography in the Dutch national screening program. In 56 pts BC was confirmed (biopsy or surgery). In the remaining 129 pts no or benign (e.g. cysts or fibroadenoma) breast disease (no BC) was diagnosed. Based on the measurement data of the VOC’s in exhaled breath, a ROC (Receiver Operating Characteristic)- curve has been created showing only a fair sensitivity and specificity of 68% and 64%, respectively. However, BC is a heterogeneous disease. Therefore, explorative analyses were performed. Indeed, no BC (n = 119) compared to either Invasive Ductal Carcinoma (IDC) (n = 38) or to Invasive Lobular Carcinoma (ILC) (n = 11) showed an improved sensitivity and specificity (IDC 71% and 55%; ILC 100% and 81% respectively). All analyses were cross-validated using a leave-one-out method.
Conclusion: The high sensitivity and specificity values found for (the relatively homogeneous) ILC indicates this technology has potential for convenient, quick, and non-invasive screening of (a)symptomatic patients. Based on our experience we expect the ROC-curve to improve for IDC when increasing numbers in several pathological subtypes can be included. Based on these results we intend to perform a larger multi-centre trial as the Aeonose electronic nose could be a convenient and cost-effective screening test for both patient and staff.
Diagnosing gastrointestinal illnesses using fecal headspace volatile organic compounds
fecal VOC analysis with Aetholab
“In our own experience, we used the Aetholab, a commercial electronic nose device (The eNose Company, Zutphen, Netherlands) in a preliminary study of 20 C. difficile PCR-positive stool and 53 C. difficile PCR-negative stool. In a similar approach using an artificial neural network for pattern recognition, we were able to classify the stool with 80% sensitivity, 85% specificity, and 84% accuracy.”
46th World Conference on Lung Health
At the 46th World Conference on Lung Health, Cape Town, South Africa (December 2-6, 2015), results from two Aeonose studies on TB were presented:
EP-138-04: Diagnosis of pulmonary and extra-pulmonary tuberculosis in Paraguay using the electronic nose (Paranose study) by R. Coronel et al,
86 participants were evaluated in 2015, 41 patients suffered from pulmonary TB and 45 were healthy controls. Preliminary analyses show sensitivity of 93% and specificity of 89 %.
A paper is in preparation.
EP-212-0: A new tuberculosis-screening tool: a hand-held electronic nose. A cross-sectional field study in Indonesia by A.M. Saktiawati et al.
87 participants from 5 groups (20 TB patients, 20 TB suspects who were later diagnosed as non TB, 20 non-TB patients, 20 healthy matched controls, and 7 MDR-TB patients) have been investigated showing a sensitivity of 92% and a specificity of 88%. More participants are being included.
